Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02566655
Other study ID # CSM/OP/2011
Secondary ID 2012-005814-20
Status Completed
Phase Phase 1
First received
Last updated
Start date September 2015
Est. completion date May 2018

Study information

Verified date November 2019
Source Red de Terapia Celular
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of intravenous infusion of fucosylated autologous bone marrow cells as a new therapy in patients with established osteoporosis by a prospective, single-center, open, non-randomized and unblinded clinical trial.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date May 2018
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Female
Age group 50 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients with established osteoporosis according to standard clinical criteria.

- Patients who give their written informed consent to participate in the study consent.

- Meet all the inclusion criteria

Exclusion Criteria:

- Patients with concomitant systemic disease in the opinion of the investigator.

- Patients with rheumatoid arthritis, ankylosing spondylitis, chronic polyarticular arthritis.

- Current patients with neoplasm or history of any malignancy in the last 10 years except basal carcinoma or epidermoid skin.

- Patients with genetic disorders that are associated with secondary osteoporosis: Hemochromatosis, hypophosphatasia, osteogenesis imperfecta, Ehlers-Danlos syndrome, Marfan syndrome, Riley Day, porphyria, storage diseases syndrome.

- Patients receiving immunosuppressive chemotherapy or that could interfere with the process of cell proliferation.

- Transplant patients: bone marrow, kidney, liver, heart, lung.

- Patients with clinical criteria and anesthetics that contraindicate well sedation or bone marrow extraction.

- Patients participating in a clinical trial in the last 6 months.

- Patients with positive serology for hepatitis B, hepatitis C or HIV.

- Patients with inability to understand informed consent.

- Patients who are pregnant or breast-feeding actively.

- Patients physically fertile, defined as all women physiologically capable of becoming pregnant, UNLESS they are using reliable methods of contraception.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Fucosylated MSC for Osteoporosis
Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA). Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access.

Locations

Country Name City State
Spain Hospital Clínico Virgen de la Arrixaca El Palmar Murcia

Sponsors (8)

Lead Sponsor Collaborator
Red de Terapia Celular BIONAND, Universidad de Málaga, IBIMA, Ciber-bbn, Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia, Grupo de Tecnología Sanitaria CIBER-BBN, Inst. Biomecánica de Valencia, Hospital Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca, Public Health Service, Murcia, Spanish National Health System

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of serious and non-serious adverse events related to the procedure. During time frame the following items will be considered:
Adverse effects related to the infusion moment. Occurrence of infectious complications after infusion of mesenchymal stem cells, because of the immunosuppressive effect of these cells.
Appearance of procedure-related neoplasias.
24 months from baseline
Secondary Number of new fractures 24 months from baseline
Secondary Pain, measured by Visual Analog Scale To measure pain, visual analogue scale (VAS) was used where 0 is no pain and 10 the worst pain imaginable. 24 months from baseline
Secondary Functionality, measured by Oswestry Disability Questionnaire To identify the functional repercussion of lumbar pain, Oswestry Disability Questionnaire for back pain or Oswestry Disability Index is used. 24 months from baseline
Secondary Quality of Life, measured by EuroQoL-5D test To measure the quality of life EuroQoL-5D psychometric test is used. 24 months from baseline
Secondary Bone resorption, measured by biochemical index Aminoterminal telopeptide of type 1 collagen in the serum (serum NTX) (%) by ELISA technique. 24 months from baseline
Secondary Bone formation, measured by biochemical index Osteocalcin in the serum by ELISA (BPG serum) (ng / mL) . 24 months from baseline
Secondary Bone formation, measured by biochemical index Bone specific alkaline phosphatase in the serum by ELISA (serum FAO) (ug / L) 24 months from baseline
Secondary Bone formation, measured by biochemical index Aminoterminal propeptide of procollagen type 1 in the serum by ELISA (serum P1NP) (ng / mL) 24 months from baseline
Secondary Bone metabolism, measured by biochemical index Osteoprotegerin (OPG) (pmol / L) in the serum by ELISA. 24 months from baseline
Secondary Bone metabolism, measured by biochemical index Ligand receptor activator of nuclear factor KB (RANKL) (pmol / L) in the serum by ELISA. 24 months from baseline
Secondary Bone Mineral Density , measured by dual energy x-ray absorptiometry (DXA) 24 months from baseline
Secondary Bone structure, measured by histomorphometric evaluation baseline and 4 months from baseline
Secondary Trabecular bone density measured by quantitative computed tomography of the radius 24 months from baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06287502 - Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis N/A
Completed NCT03822078 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women Phase 1
Recruiting NCT05845021 - Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04736693 - Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Completed NCT02922478 - Role of Comorbidities in Chronic Heart Failure Study
Recruiting NCT02635022 - Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Active, not recruiting NCT02617303 - Prevention of Falls and Its Consequences in Elderly People N/A
Completed NCT02559648 - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Phase 2
Completed NCT03420716 - Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women N/A
Not yet recruiting NCT02223572 - Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture N/A
Not yet recruiting NCT01854086 - Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday N/A
Completed NCT02003716 - DeFRA Questionnaire as an Anamnestic Form N/A
Unknown status NCT01913834 - Nasally and sc Administered Teriparatide in Healthy Volunteers Phase 1
Completed NCT02143674 - Muscle Strengthening Exercises and Global Stretching in Elderly N/A
Completed NCT01757340 - Calorie Restriction With Leucine Supplementation N/A
Completed NCT01401556 - C-STOP Fracture Trial N/A
Completed NCT01694784 - Understanding and Discouraging Overuse of Potentially Harmful Screening Tests N/A